Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model

Gabril, Manal; Onita, Toru; Ji, P G; Sakai, Hideki; Chan, Franky L.; Koropatnick, James; Chin, Joseph L.; Moussa, Madeleine; Xuan, Jim W.

doi:10.1038/sj.gt.3301895

Cited by 51 publications

(103 citation statements)

References 28 publications

Supporting

Mentioning

100

Contrasting

Order By: Relevance

“…In this study, macroscopic tumors mean prostate tumor larger than 1 mm in diameter. As previously reported, PSP-TGMAP mice classified as negative by ultrasound still possess microscopic foci of various degrees of mouse prostate cancer that have not formed large, fast-growing masses (Gabril et al 2002;Duan et al 2005).…”

Section: Dissection Of the Mouse Modelmentioning

confidence: 53%

“…Transgenic (PSP-TGMAP) mice were identified by a quick polymerase chain reaction (PCR) genotyping protocol as previously reported (Gabril et al 2002;Duan et al 2005). After imaging, mice with tumors were euthanized and the dissection procedure was followed (Gabril et al 2002;Duan et al 2005). In brief, the prostate tissue including the ventral prostate (VP), dorsolateral prostate (DLP), anterior prostate (AP, the coagulation gland), the male accessory gland (SV, seminal vesicles), and the whole bladder were removed for gross examination and serial sectioning.…”

Section: Dissection Of the Mouse Modelmentioning

confidence: 99%

“…In brief, the prostate tissue including the ventral prostate (VP), dorsolateral prostate (DLP), anterior prostate (AP, the coagulation gland), the male accessory gland (SV, seminal vesicles), and the whole bladder were removed for gross examination and serial sectioning. Histopathological characterization and standard definitions of various degrees of well, moderately and poorly differentiated CaPs were classified as we previously reported (Gabril et al 2002;Duan et al 2005).…”

Section: Dissection Of the Mouse Modelmentioning

confidence: 99%

Section: Dissection Of the Mouse Modelmentioning

confidence: 99%

“…This paper reports the first use of three-dimensional ultrasound micro-imaging for measuring tumor progression in a genetically engineered mouse model, the transgenic mouse adenocarcinoma of the prostate (TGMAP), where SV40 T-Ag expression is directed to the prostate by the prostate secretory protein of 94 amino acids (PSP94) gene promoter/enhancer region (Gabril et al 2002;Duan et al 2005). The following sections present cross-sectional and longitudinal imaging studies that demonstrate the sensitivity and specificity of three-dimensional ultrasound for detecting prostate tumors in mice when the tumors are too small to be palpable and illustrate the use of ultrasound imaging to measure the rapid growth of murine prostate tumors in situ.…”

mentioning

confidence: 99%

See 4 more Smart Citations

The Use of Three-Dimensional Ultrasound Micro-Imaging to Monitor Prostate Tumor Development in a Transgenic Prostate Cancer Mouse Model

Wang

et al. 2005

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Longitudinal studies of mouse cancer models required large cohorts since autopsy was the only reliable method to evaluate treatment efficacy. This paper reports the use of high-resolution three-dimensional ultrasound micro-imaging to monitor prostate tumor development in genetically engineered mice. Twenty-nine genetically engineered prostate cancer mice, including castrated and uncastrated mice, were imaged by three-dimensional ultrasound. Qualitative comparisons of three-dimensional ultrasound images with histology sections of prostate tumors demonstrate the ability of ultrasound to accurately depict the size and shape of malignant masses in live mice. The correlation coefficient of tumor diameter measurements performed in vivo with three-dimensional ultrasound and at autopsy was 0.997. Prospective tumor detection sensitivity and specificity were 91.7% and 100%. Representative exponential growth curves constructed via longitudinal ultrasound imaging indicated diameter doubling times from 10 to 37 days for four prostate tumors during an initial period of rapid progression. Three-dimensional ultrasound will likely become the micro-imaging modality most readily adopted for mouse pre-clinical trial studies. ultrasound; prostate neoplasms; mouse model

show abstract

Section: Dissection Of the Mouse Modelmentioning

confidence: 53%

Section: Dissection Of the Mouse Modelmentioning

confidence: 99%

Section: Dissection Of the Mouse Modelmentioning

confidence: 99%

Section: Dissection Of the Mouse Modelmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

The Use of Three-Dimensional Ultrasound Micro-Imaging to Monitor Prostate Tumor Development in a Transgenic Prostate Cancer Mouse Model

Wang

et al. 2005

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

Models for Prostate Cancer

Jain

Vashistha

Gross

et al. 2007

The Cancer Handbook

View full text Add to dashboard Cite

Translational research examining the progression and treatment of prostate cancer (PCa) is benefited significantly from the availability of models that faithfully mimic the in vivo disease. It is advantageous if the model system maximally recapitulates the myriad complex relationships that contribute towards prostate carcinogenesis. These include hormonal and genetic status of the host, immune response to the tumour, environmental and dietary influences, tumour epithelial and stromal interactions, local and systemic influences in the host including, the tumour tissue type, adjacent tissues, and metastatic preferences. The currently available models of prostate cancer have been divided as those that are influenced by, or are independent of, the immune systems of the hosts. The final section describes models that have specifically attempted to address bone metastasis in prostate cancer. These model systems are of paramount importance in the study of the biology of prostate cancer and to help develop new therapeutic strategies to fight the various “biologic states” of prostate cancer.

show abstract

Mouse PSP94 expression is prostate tissue‐specific as demonstrated by a comparison of multiple antibodies against recombinant proteins

Thota

Karajgikar

Duan

et al. 2003

J of Cellular Biochemistry

View full text Add to dashboard Cite

Prostate tissue-specific gene expression is crucial for driving potentially therapeutic genes to target specifically to the prostate. Prostate secretory protein of 94 amino acids (PSP94), also known as beta-MSP (microseminoprotein), is one of the three most abundant secretory proteins of the prostate gland, and is generally considered to be prostate tissue-specific. We have previously demonstrated that the expression of the rat PSP94 gene is strictly prostate tissue-specific by an antibody against a recombinant rat PSP94. In order to study prostate targeting utilizing the PSP94 gene in a mouse pre-clinical experimental model, we need to establish antibodies against mouse PSP94 to confirm if it is prostate tissue-specific as well. In this study, firstly we raised a polyclonal antibody against a recombinant glutathione-S-transferase- (GST-) mouse mature form of PSP94. However, it showed very poor immunoreactivity against prostate tissue PSP94 as tested in Western blotting experiments. Neither antibodies against rat PSP94 nor mouse PSP94 showed significant cross-reactivity. Thus a second antibody was established against a recombinant mouse mature PSP94 containing N-terminal polyhistidines, and stronger immunoreactivity against mouse prostate tissue PSP94 was identified in Western blotting experiments. Both of these antibodies showed immunohistochemical reactivity, while the latter showed stronger reactivity in IHC when tested with different fixatives. By studying tissue distribution, we demonstrated that, as with rat PSP94, mouse PSP94 is strictly prostate tissue-specific in experiments of both Western blotting and immunohistochemistry (IHC). This conclusion was also derived from a comparison among antibodies against human, rat, and mouse PSP94, showing very different immunoreactivities in Western blotting and IHC. Finally, a competitive assay between different species was performed. We demonstrated that antibodies against PSP94 from different species (human, primate, rodents) have poor cross-reactivities. These observations also indicate that the PSP94 gene is a rapidly evolving gene in all species. Results from this study have led to the possibility of utilizing PSP94 as a targeting agent specifically to the prostate in a mouse experimental model.

show abstract

Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model

Cited by 51 publications

References 28 publications

The Use of Three-Dimensional Ultrasound Micro-Imaging to Monitor Prostate Tumor Development in a Transgenic Prostate Cancer Mouse Model

The Use of Three-Dimensional Ultrasound Micro-Imaging to Monitor Prostate Tumor Development in a Transgenic Prostate Cancer Mouse Model

Models for Prostate Cancer

Mouse PSP94 expression is prostate tissue‐specific as demonstrated by a comparison of multiple antibodies against recombinant proteins

Contact Info

Product

Resources

About